Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com 4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug